Cargando…
Effectiveness of Secondary Risk–Reducing Strategies in Patients With Unilateral Breast Cancer With Pathogenic Variants of BRCA1 and BRCA2 Subjected to Breast-Conserving Surgery: Evidence-Based Simulation Study
BACKGROUND: Approximately 62% of patients with breast cancer with a pathogenic variant (BRCA1 or BRCA2) undergo primary breast-conserving therapy. OBJECTIVE: The study aims to develop a personalized risk management decision support tool for carriers of a pathogenic variant (BRCA1 or BRCA2) who under...
Autores principales: | Maksimenko, Jelena, Rodrigues, Pedro Pereira, Nakazawa-Miklaševiča, Miki, Pinto, David, Miklaševičs, Edvins, Trofimovičs, Genadijs, Gardovskis, Jānis, Cardoso, Fatima, Cardoso, Maria João |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JMIR Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837710/ https://www.ncbi.nlm.nih.gov/pubmed/36580360 http://dx.doi.org/10.2196/37144 |
Ejemplares similares
-
Correction: Effectiveness of Secondary Risk–Reducing Strategies in Patients With Unilateral Breast Cancer With Pathogenic Variants of BRCA1 and BRCA2 Subjected to Breast-Conserving Surgery: Evidence-Based Simulation Study
por: Maksimenko, Jelena, et al.
Publicado: (2023) -
Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer
por: MAKSIMENKO, JELENA, et al.
Publicado: (2014) -
BRCA1 mutation in the Triple- Negative Breast Cancer Group
por: Maksimenko, Jelena, et al.
Publicado: (2012) -
Ultrasound guided needle biopsy of axilla to evaluate nodal metastasis after preoperative systemic therapy in cohort of 106 breast cancers enriched with BRCA1/2 pathogenic variant carriers
por: Līcīte, Baiba, et al.
Publicado: (2021) -
BRCA1/2 mutation screening in high-risk breast/ovarian cancer families and sporadic cancer patient surveilling for hidden high-risk families
por: Berzina, Dace, et al.
Publicado: (2013)